Going back to class I: MHC and immunotherapies for childhood cancer.
about
Immunotherapy of Childhood SarcomasThe Janus Face of Death Receptor Signaling during Tumor ImmunoeditingCellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma.Characterization of MHC Class I and β-2-Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune-Based Therapeutic Trials.Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines.Progress and opportunities for immune therapeutics in osteosarcoma.Unleashing the immune response against childhood solid cancers.Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
P2860
Q26795369-D6611428-A8E4-4DB1-8503-B6EF6430214FQ28070036-D21D7108-9026-4BF4-9F0E-84CEDEF2598BQ36261159-450D45BC-E833-47AD-80E5-925E3F6FEA6CQ38670099-3D4694C2-446B-4A8B-93A0-62A06549C026Q38730989-504DC179-E30B-4228-BD95-D2D03E6B9673Q38784430-4B3CFFFF-8B64-420A-A63E-B8DF97B91BC0Q38819030-A9217AB2-CF74-43B2-BAEA-D71414479B0CQ38827604-479A2BF3-53EB-4E3B-B236-EDAC9568D997Q38948905-4B3D0424-DC33-4EB8-9D35-0F7E57FD3DEEQ39224315-C3260D45-3BF5-4EA2-92DD-6D0F3A3DE781Q47144771-BF39EF4F-D5D3-4F8D-9943-E33DC970F2FCQ47449809-656C1538-7658-4779-A918-94D78988450EQ47569690-1F685C32-E4A1-4258-AC13-66CD73A2A30BQ53697011-4FB24D2B-C83D-40CB-A73A-C1EB2D51997BQ55262681-BAFA6D27-C9B4-4DF9-97BD-200A8BFAE106Q57191808-97FFF86A-62BC-4DEB-96AC-D56BF7D1AAD6
P2860
Going back to class I: MHC and immunotherapies for childhood cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Going back to class I: MHC and immunotherapies for childhood cancer.
@ast
Going back to class I: MHC and immunotherapies for childhood cancer.
@en
type
label
Going back to class I: MHC and immunotherapies for childhood cancer.
@ast
Going back to class I: MHC and immunotherapies for childhood cancer.
@en
prefLabel
Going back to class I: MHC and immunotherapies for childhood cancer.
@ast
Going back to class I: MHC and immunotherapies for childhood cancer.
@en
P2093
P2860
P356
P1476
Going back to class I: MHC and immunotherapies for childhood cancer
@en
P2093
Chun-Yu Chen
Crystal L Mackall
Edwin M Horwitz
Jennifer L Leddon
Timothy P Cripe
P2860
P304
P356
10.1002/PBC.25359
P577
2014-12-18T00:00:00Z